Trial Profile
A trial evaluating the risk of Natalizumab discontinuation in patients with multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Oct 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 15 Oct 2016 New trial record